5-aminosalicylates in inflammatory bowel disease and chronic renal failure: Authors' reply

被引：0
|
作者：
Muller, AF [1 ]
Stevens, PE
McIntyre, AS
Ellison, H
Logan, RF
机构：
[1] Kent & Canterbury Hosp, Dept Gastroenterol, Canterbury, Kent, England
[2] Kent & Canterbury Hosp, Dept Nephrol, Canterbury, Kent, England
[3] Wycombe Gen Hosp, Dept Med, Wycombe, Bucks, England
[4] British Soc Gastroenterol, London, England
[5] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2005年 / 22卷 / 06期
关键词：
D O I：
10.1111/j.1365-2036.2005.02618.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：579 / 580
页数：2
相关论文
共 50 条
  • [21] Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias - authors' reply
    Robinson, A.
    Hankins, M.
    Wiseman, G.
    Jones, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (03) : 345 - 346
  • [22] Effect of 5-aminosalicylates (5-ASAS) on renal function in patients with inflammatory bowel disease (IBD): 4-year follow-up study
    Gisbert, Javier P.
    Luna, M.
    Gonzalez-lama, Y.
    Mate, J.
    GASTROENTEROLOGY, 2007, 132 (04) : A176 - A176
  • [23] AMINOSALICYLATES IN THE TREATMENT OF CHRONIC INFLAMMATORY BOWEL-DISEASE
    HARTMANN, F
    PLAUTH, M
    INTERNIST, 1990, 31 (11): : 702 - 706
  • [24] Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease
    Bonovas, S.
    Fiorino, G.
    Lytras, T.
    Nikolopoulos, G.
    Peyrin-Biroulet, L.
    Danese, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (09) : 1179 - 1192
  • [25] Differences in expression of PPARγ in small intestine vs. colon impact the effect of 5-aminosalicylates in inflammatory bowel disease
    Bakke, I.
    Bruland, T.
    Eriksen, K. S.
    Skovdahl, H. K.
    Gopalakrishnan, S.
    Thorsvik, S.
    Granlund, A. V. B.
    Sandvik, A. K.
    Ostvik, A. E.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S182 - S182
  • [26] Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Park, Jihye
    Cheon, Jae Hee
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (05): : 895 - 905
  • [27] Chronic inflammatory bowel disease in a pseudotumoral form improving on aminosalicylates
    Maamouri, N.
    Guellouz, S.
    Belkahla, N.
    Kchir, H.
    Mohsni, B.
    Haouet, S.
    Chouaib, S.
    Zitouna, M. M.
    Ben Mami, N.
    ACTA ENDOSCOPICA, 2011, 41 (05) : 301 - 302
  • [28] 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry
    Ungaro, R.
    Brenner, E.
    Agrawal, M.
    Gearry, R. B.
    Kaplan, G. O.
    Kissous-Hunt, M.
    Ng, S. C.
    Rahier, J. F.
    Reinisch, W.
    Steinwurz, F.
    Zhang, X.
    Lewis, J. D.
    Kappelman, M. D.
    Colombel, J. F.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S006 - S007
  • [29] Tolerability of aminosalicylates in inflammatory bowel disease
    Ishaq, S
    Green, JRB
    BIODRUGS, 2001, 15 (05) : 339 - 349
  • [30] Aminosalicylates in the treatment of inflammatory bowel disease
    Sutherland, LR
    INFLAMMATORY BOWEL DISEASES, 1998, 4 (02) : 113 - 113
12345